76.09
price up icon4.06%   2.97
after-market アフターアワーズ: 76.09
loading
前日終値:
$73.12
開ける:
$73
24時間の取引高:
2.08M
Relative Volume:
0.75
時価総額:
$12.32B
収益:
$705.14M
当期純損益:
$-453.90M
株価収益率:
-25.03
EPS:
-3.04
ネットキャッシュフロー:
$-551.29M
1週間 パフォーマンス:
+6.35%
1か月 パフォーマンス:
+6.21%
6か月 パフォーマンス:
+127.13%
1年 パフォーマンス:
+124.19%
1日の値動き範囲:
Value
$73.00
$76.31
1週間の範囲:
Value
$70.69
$76.31
52週間の値動き範囲:
Value
$23.95
$76.78

Ionis Pharmaceuticals Inc Stock (IONS) Company Profile

Name
名前
Ionis Pharmaceuticals Inc
Name
セクター
Healthcare (1129)
Name
電話
(760) 931-9200
Name
住所
2855 GAZELLE COURT, CARLSBAD, CA
Name
職員
927
Name
Twitter
@ionispharma
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
IONS's Discussions on Twitter

IONS を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
IONS
Ionis Pharmaceuticals Inc
76.09 11.84B 705.14M -453.90M -551.29M -3.04
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
426.76 107.15B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
755.90 77.46B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
436.38 58.90B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ARGX
Argen X Se Adr
918.92 56.55B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
198.76 42.58B 447.02M -1.18B -906.14M -6.1812

Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-10-08 アップグレード JP Morgan Neutral → Overweight
2025-09-26 アップグレード Goldman Sell → Neutral
2025-09-03 アップグレード BMO Capital Markets Market Perform → Outperform
2025-07-31 アップグレード Morgan Stanley Equal-Weight → Overweight
2025-07-01 アップグレード Barclays Equal Weight → Overweight
2025-04-07 開始されました H.C. Wainwright Buy
2025-03-31 開始されました Redburn Atlantic Neutral
2024-08-02 ダウングレード BMO Capital Markets Outperform → Market Perform
2024-07-24 アップグレード Leerink Partners Market Perform → Outperform
2024-07-16 再開されました Jefferies Buy
2024-06-14 アップグレード Bernstein Underperform → Mkt Perform
2024-04-10 アップグレード Wolfe Research Peer Perform → Outperform
2024-01-02 アップグレード BofA Securities Neutral → Buy
2023-10-23 アップグレード BofA Securities Underperform → Neutral
2023-09-29 開始されました Raymond James Strong Buy
2023-07-31 アップグレード Citigroup Neutral → Buy
2023-06-07 再開されました Piper Sandler Overweight
2023-05-04 アップグレード Citigroup Sell → Neutral
2023-03-21 開始されました Bernstein Underperform
2022-12-21 ダウングレード Morgan Stanley Overweight → Equal-Weight
2022-09-09 再開されました Morgan Stanley Overweight
2022-07-18 再開されました Oppenheimer Outperform
2022-03-31 再開されました Piper Sandler Overweight
2022-03-01 開始されました Citigroup Sell
2022-03-01 開始されました Guggenheim Buy
2022-02-01 ダウングレード BofA Securities Buy → Underperform
2021-12-14 アップグレード William Blair Mkt Perform → Outperform
2021-05-07 アップグレード UBS Sell → Neutral
2021-03-01 アップグレード Barclays Underweight → Equal Weight
2020-12-16 開始されました UBS Sell
2020-12-15 アップグレード Cowen Market Perform → Outperform
2020-09-14 再開されました JP Morgan Neutral
2020-09-02 開始されました The Benchmark Company Hold
2020-06-01 再開されました Oppenheimer Outperform
2020-05-13 開始されました RBC Capital Mkts Outperform
2020-03-05 開始されました Citigroup Buy
2019-12-13 開始されました Oppenheimer Outperform
2019-11-13 開始されました BofA/Merrill Buy
2019-11-07 ダウングレード Morgan Stanley Equal-Weight → Underweight
2019-09-10 アップグレード Bernstein Mkt Perform → Outperform
2018-08-08 繰り返されました Stifel Hold
2018-08-07 繰り返されました Stifel Hold
2018-05-08 ダウングレード Evercore ISI Outperform → In-line
2017-10-06 再開されました Goldman Sell
2017-08-17 開始されました Evercore ISI Outperform
2017-08-09 繰り返されました Stifel Hold
2017-03-10 ダウングレード Goldman Neutral → Sell
2016-12-28 繰り返されました BMO Capital Markets Outperform
2016-12-27 繰り返されました Leerink Partners Mkt Perform
すべてを表示

Ionis Pharmaceuticals Inc (IONS) 最新ニュース

pulisher
Nov 21, 2025

Can Ionis Pharmaceuticals Inc. (ISI) stock sustain revenue momentumFed Meeting & Daily Oversold Bounce Ideas - newser.com

Nov 21, 2025
pulisher
Nov 21, 2025

Is Ionis Pharmaceuticals Inc. stock a defensive play in 2025Weekly Trading Summary & Weekly Return Optimization Plans - newser.com

Nov 21, 2025
pulisher
Nov 20, 2025

Insider Sell: Joan Herman Sells 44,000 Shares of Ionis Pharmaceuticals Inc (IONS) - GuruFocus

Nov 20, 2025
pulisher
Nov 20, 2025

Can Ionis Pharmaceuticals Inc. (ISI) stock stage a strong rebound this quarterWeekly Volume Report & Weekly Breakout Opportunity Watchlist - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

Is Ionis Pharmaceuticals Inc. (ISI) stock undervalued after correctionWatch List & Fast Entry Momentum Alerts - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

Will Ionis Pharmaceuticals Inc. stock pay special dividendsJuly 2025 Sector Moves & Safe Swing Trade Setups - newser.com

Nov 20, 2025
pulisher
Nov 19, 2025

Arrowhead’s Redemplo Approval Sets Up Standoff With Ionis’s Tryngolza - Citeline News & Insights

Nov 19, 2025
pulisher
Nov 19, 2025

How Ionis Pharmaceuticals Inc. stock trades during market volatilityQuarterly Profit Report & AI Driven Price Forecasts - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Why Ionis Pharmaceuticals Inc. stock attracts high net worth investorsWeekly Profit Analysis & Real-Time Chart Pattern Alerts - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Arrowhead Pharmaceuticals Steps Into The Rare Disease Market - Finimize

Nov 19, 2025
pulisher
Nov 19, 2025

Price momentum metrics for Ionis Pharmaceuticals Inc. explained2025 Market Outlook & Intraday High Probability Setup Alerts - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Is Ionis Pharmaceuticals Inc. (ISI) stock attractive post correctionPortfolio Gains Report & Consistent Profit Trade Alerts - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

How Ionis Pharmaceuticals Inc. (ISI) stock compares with tech leaders2025 Momentum Check & Stock Portfolio Risk Management - newser.com

Nov 19, 2025
pulisher
Nov 18, 2025

With FDA Approval for RNAi Drug, Arrowhead Pharma Starts Price War With Rival Ionis - MedCity News

Nov 18, 2025
pulisher
Nov 18, 2025

US FDA approves Arrowhead's genetic disorder drug - Reuters

Nov 18, 2025
pulisher
Nov 18, 2025

Arrowhead’s plozasiran cleared for FCS; Ionis patent duel awaits - BioWorld MedTech

Nov 18, 2025
pulisher
Nov 18, 2025

RNAi biotech Arrowhead wins first FDA approval - BioPharma Dive

Nov 18, 2025
pulisher
Nov 17, 2025

Ionis Pharmaceuticals Completes $770M Convertible Notes Offering - TipRanks

Nov 17, 2025
pulisher
Nov 17, 2025

Ionis Pharmaceuticals (IONS) Price Target Increased by 10.27% to 85.25 - Nasdaq

Nov 17, 2025
pulisher
Nov 17, 2025

Arrowhead Pharmaceuticals: Important Catalysts And Some Challenges Ahead (NASDAQ:ARWR) - Seeking Alpha

Nov 17, 2025
pulisher
Nov 17, 2025

DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE) - BioSpace

Nov 17, 2025
pulisher
Nov 15, 2025

Can Ionis Pharmaceuticals Inc. stock sustain free cash flow growthTrade Signal Summary & Risk Adjusted Buy and Sell Alerts - newser.com

Nov 15, 2025
pulisher
Nov 15, 2025

What Recent Clinical Trial Updates Mean for Ionis Pharmaceuticals Stock Valuation in 2025 - Yahoo Finance

Nov 15, 2025
pulisher
Nov 14, 2025

Will Ionis Pharmaceuticals Inc. stock deliver better than expected guidanceTrade Signal Summary & Expert Approved Momentum Ideas - newser.com

Nov 14, 2025
pulisher
Nov 14, 2025

Biogen Completes Acquisition of Alcyone Therapeutics - Benzinga

Nov 14, 2025
pulisher
Nov 14, 2025

Ionis Pharmaceuticals stock rises after positive EU regulatory opinion By Investing.com - Investing.com India

Nov 14, 2025
pulisher
Nov 14, 2025

Ionis Pharmaceuticals stock rises after positive EU regulatory opinion - Investing.com

Nov 14, 2025
pulisher
Nov 14, 2025

Sanofi, Lilly among winners of EU drug recommendations this week - Seeking Alpha

Nov 14, 2025
pulisher
Nov 14, 2025

Ionis Pharmaceuticals (IONS) Advances with European Review for D - GuruFocus

Nov 14, 2025
pulisher
Nov 14, 2025

Is Ionis Pharmaceuticals Inc. stock in correction or buying zone2025 Market WrapUp & Intraday High Probability Alerts - Fundação Cultural do Pará

Nov 14, 2025
pulisher
Nov 14, 2025

Ionis Pharmaceuticals Says Dawnzera Recommended for Approval in EU for Hereditary Angioedema - MarketScreener

Nov 14, 2025
pulisher
Nov 14, 2025

EU committee recommends approval of Ionis’ HAE treatment By Investing.com - Investing.com Canada

Nov 14, 2025
pulisher
Nov 14, 2025

DAWNZERA Receives Positive Opinion From CHMP, Recommended For Approval In EU For Hereditary Angioedema - TradingView

Nov 14, 2025

Ionis Pharmaceuticals Inc (IONS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$38.92
price up icon 1.38%
$30.45
price up icon 1.36%
$102.06
price up icon 0.29%
$95.59
price down icon 1.42%
biotechnology ONC
$347.72
price down icon 0.45%
$198.76
price down icon 0.44%
大文字化:     |  ボリューム (24 時間):